AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

Compositions and Methods for the Treatment of Respiratory Conditions via NKG2D Inhibition

Technology Benefits: antibody or protein therapy effective at the cellular leveldecreased possibility of side effects due to high selectivity and identification of a specific targetsuitable for treating a number of respiratory conditions, including asthma, steroid-resistant asthma and COPD

Technology Application: treating or preventing respiratory conditions such as asthma, steroid-resistant asthma, and COPD

Detailed Technology Description: None

Supplementary Information: Patent Number: WO2013032943A1
Application Number: WO2012US52369A
Inventor: RAULET, David | HAWORTH, Oliver | LOCKSLEY, Richard | BORCHERS, Michael
Priority Date: 26 Aug 2011
Priority Number: WO2013032943A1
Application Date: 24 Aug 2012
Publication Date: 7 Mar 2013
IPC Current: A61K0039395 | A61K004800 | A61P001100 | A61P001106
Assignee Applicant: The Regents of the University of California
Title: METHODS AND COMPOSITIONS FOR THE TREATMENT OF RESPIRATORY CONDITIONS VIA NKG2D INHIBITION | PROCÉDÉS ET COMPOSITIONS POUR LE TRAITEMENT DE PATHOLOGIES RESPIRATOIRES PAR INHIBITION DE NKG2D
Usefulness: METHODS AND COMPOSITIONS FOR THE TREATMENT OF RESPIRATORY CONDITIONS VIA NKG2D INHIBITION | PROCÉDÉS ET COMPOSITIONS POUR LE TRAITEMENT DE PATHOLOGIES RESPIRATOIRES PAR INHIBITION DE NKG2D
Summary: The method, composition, and kit are useful for treating or preventing a respiratory condition, where the respiratory condition is asthma or chronic obstructive pulmonary disease (COPD) (all claimed).
Novelty: Treating or preventing a respiratory condition comprises administering to the subject a composition comprising an inhibitor of killer cell lectin-like receptor subfamily K, member 1 (NKG2D)-mediated activation of leukocytes

Industry: Biomedical

Sub Category: Medical Composition

Application No.: 20140248289

Others: Publication
NKG2D Mediates NK Cell Hyperresponsiveness and Influenza-Induced Pathologies in a Mouse Model of COPD

Tech ID/UC Case
22499/2012-099-0

Related Cases
2012-099-0

*Abstract: Respiratory conditions such as chronic obstructive pulmonary disease (COPD) and asthma afflict millions of people each year. COPD is characterized by peribronchial and perivascular inflammation and largely irreversible airflow obstruction. Asthma is characterized by infiltration of leukocytes subsets including eosinophils, macrophages and lymphocytes including natural killer (NK) cells that contribute to the sustained inflammation. There is no cure for these conditions and individuals experience varied success with current treatment modalities.

Investigators at UC Berkeley have revealed important roles for NK cells in the development and progression of COPD and asthma, which indicates that these mechanisms are controlled by the presence and function of NKG2D. A therapeutic effect is achieved by administering agents that inhibit NKG2D-mediated activation of leukocytes, such as antibodies or soluble ligands or receptors that block NKG2D or its ligands.

*IP Issue Date: Sep 4, 2014

*Principal Investigator: Name: Oliver Haworth
Department:

Name: David Raulet
Department:

Name: Richard Locksley
Department:

Name: Michael Borchers
Department:

Country/Region: USA

For more information, please click Here